Xencor Inc (NASDAQ:XNCR) – Equities research analysts at Leerink Swann lifted their FY2018 earnings per share (EPS) estimates for Xencor in a report released on Monday, November 5th. Leerink Swann analyst J. Chang now forecasts that the biopharmaceutical company will earn ($1.56) per share for the year, up from their prior forecast of ($2.40). Leerink Swann also issued estimates for Xencor’s Q4 2018 earnings at ($0.59) EPS and FY2019 earnings at ($2.07) EPS.
Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.57. The company had revenue of $29.04 million during the quarter.
NASDAQ XNCR opened at $37.88 on Thursday. The firm has a market capitalization of $2.27 billion, a price-to-earnings ratio of -36.08 and a beta of 1.73. Xencor has a 12-month low of $19.50 and a 12-month high of $48.38.
Institutional investors have recently modified their holdings of the stock. Sei Investments Co. purchased a new position in shares of Xencor during the second quarter worth $138,000. Public Employees Retirement Association of Colorado raised its holdings in shares of Xencor by 64.7% during the third quarter. Public Employees Retirement Association of Colorado now owns 4,404 shares of the biopharmaceutical company’s stock worth $172,000 after purchasing an additional 1,730 shares during the last quarter. UBS Group AG raised its holdings in shares of Xencor by 449.9% during the first quarter. UBS Group AG now owns 5,972 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 4,886 shares during the last quarter. Bank of Montreal Can purchased a new position in shares of Xencor during the second quarter worth $232,000. Finally, Amalgamated Bank acquired a new stake in Xencor during the second quarter valued at $262,000. 83.03% of the stock is owned by hedge funds and other institutional investors.
In related news, major shareholder John S. Stafford III sold 1,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $48.05, for a total transaction of $48,050.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Edgardo Baracchini, Jr. sold 50,000 shares of the firm’s stock in a transaction on Monday, August 13th. The stock was sold at an average price of $40.16, for a total transaction of $2,008,000.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,341 shares of company stock valued at $5,390,865. 4.70% of the stock is currently owned by corporate insiders.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
See Also: Trading Penny Stocks
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.